Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Palisade Bio (PALI) Change in Receivables (2016 - 2023)

Palisade Bio (PALI) has disclosed Change in Receivables for 13 consecutive years, with $250000.0 as the latest value for Q1 2023.

  • On a quarterly basis, Change in Receivables changed N/A to $250000.0 in Q1 2023 year-over-year; TTM through Mar 2024 was $334000.0, a 21.45% increase, with the full-year FY2021 number at -$84000.0, down 242.37% from a year prior.
  • Change in Receivables was $250000.0 for Q1 2023 at Palisade Bio, up from $84000.0 in the prior quarter.
  • In the past five years, Change in Receivables ranged from a high of $250000.0 in Q1 2023 to a low of -$108751.0 in Q3 2019.
  • A 5-year average of -$1916.1 and a median of -$32545.0 in 2019 define the central range for Change in Receivables.
  • Peak YoY movement for Change in Receivables: soared 181.1% in 2020, then plummeted 2778.05% in 2021.
  • Palisade Bio's Change in Receivables stood at -$40090.0 in 2019, then soared by 114.97% to $6000.0 in 2020, then plummeted by 1083.33% to -$59000.0 in 2021, then soared by 242.37% to $84000.0 in 2022, then soared by 197.62% to $250000.0 in 2023.
  • Per Business Quant, the three most recent readings for PALI's Change in Receivables are $250000.0 (Q1 2023), $84000.0 (Q4 2022), and -$59000.0 (Q3 2021).